Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julaiha Ariff

Internal Medicine Surprise, AZ Medical Doctor

NPI 1831188689 CMS profile 82807

18731 N. Reems Rd, #680, Surprise, AZ 85374

Open in the dashboard

General payments

$2,943

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julaiha Ariff of Surprise, AZ is reported in the CMS Open Payments database as having received $2,943 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94 4
2024 General $16 1
2023 General $504 20
2022 General $624 20
2021 General $501 27
2020 General $407 22
2019 General $797 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julaiha Ariff
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Julaiha Ariff were reported at $94. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Julaiha Ariff Internal Medicine median Middle half National median
2019 $797 $159 $48–$570 $163
2020 $407 $119 $33–$402 $114
2021 $501 $135 $37–$521 $132
2022 $624 $141 $42–$496 $149
2023 $504 $149 $45–$519 $160
2024 $16 $154 $47–$537 $164
2025 $94 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $776 47 payments
  2. AstraZeneca Pharmaceuticals LP $224 8 payments
  3. Actelion Pharmaceuticals US, Inc. $194 9 payments
  4. AbbVie, Inc. $167 9 payments
  5. Astellas Pharma US Inc $159 5 payments
  6. E.R. Squibb & Sons, L.L.C. $156 2 payments
  7. Abbott Laboratories $149 8 payments
  8. Mylan Specialty L.P. $122 6 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $93 4 payments
  10. Pfizer Inc. $91 5 payments
  11. Other $811 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,868 139 payments
  2. Education $75 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $561 34 payments
  2. OPSUMIT $194 9 payments
  3. UPTRAVI $170 8 payments
  4. ELIQUIS $156 2 payments
  5. SPIRIVA RESPIMAT $149 6 payments
  6. LOKELMA $122 1 payment
  7. VRAYLAR $116 6 payments
  8. ANORO ELLIPTA $108 6 payments
  9. ANORO $92 6 payments
  10. RYBELSUS $87 1 payment
  11. Other $1,965 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 161 drugs

Part D claims

13,043

Median for Internal Medicine: 777

Drug cost

$984,363

Median for Internal Medicine: $73,373

Branded share of claims

14.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 101 $168,074
Eliquis Apixaban Brand 80 $114,701
Farxiga Dapagliflozin Propanediol Brand 55 $81,728
Mounjaro Tirzepatide Brand 63 $71,942
Jardiance Empagliflozin Brand 50 $69,926
Trulicity Dulaglutide Brand 34 $66,891
Januvia Sitagliptin Phosphate Brand 53 $52,827
Xarelto Rivaroxaban Brand 33 $47,296
Myrbetriq Mirabegron Brand 41 $28,624
Repatha Sureclick Evolocumab Brand 21 $23,439

The 10 drugs with the highest cost, of 161 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$392,534

Of which drugs: $49,408

Medicare patients

712

Average age 76

Services billed

7,068

512 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 57%
Chronic kidney disease 31%
Diabetes 25%
Ischemic heart disease 24%
Osteoporosis 23%
Depression 19%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 141 141 $40,891
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 104 104 $8,427

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record